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INTRODUCTION 
Direct-acting antivirals (DAAs) are currently the treatment of 
choice for chronic hepatitis C virus (HCV) infection.1 Several treat-
ment options are available for chronic HCV such as nucleoside 
polymerase inhibitors like sofosbuvir (SOF), non-nucleoside poly-
merase inhibitors such as dasabuvir (DSV), protease inhibitors (PIs) 
such as simeprevir (SMV), paritaprevir boosted with ritonavir 
(PTVr), and grazoprevir (GZR), and NS5A inhibitors such as ledi-
pasvir (LDV), ombitasvir (OBV), daclatasvir (DCV), elbasvir (EBV), 
and velpatasvir (VEL) have proven highly effective for eradicating 
HCV.1-3 Another PI, asunaprevir (ASV), has been approved in some 
Asian countries.3 These drugs are usually given in combination to 
increase their effectiveness and prevent the emergence of har-
bored HCV resistance-associated substitutions (RASs).2 The fol-
lowing DAA combination regimens are currently used in clinical 
practice for patients infected with HCV genotypes (GT) 1 and 4: 1) 
SMV plus SOF ± ribavirin (RBV); 2) SOF plus an NS5A inhibitor 
Management of direct antiviral agent failures
María Buti1,2, and Rafael Esteban1,2
1Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron and Universitat Autònoma de Barcelona, Barcelona; 
2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Madrid, Spain
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting 
antiviral agents (DAAs). Most HCV patients treated with these drugs achieve viral elimination, but 1% to 15% fail to 
attain this objective. Treatment failures are usually related to relapse, and less often to on-treatment viral breakthrough. 
HCV drug resistant associated substitutions are detected in most patients who do not eliminate the virus. The risk 
of developing these variants depends on host- and virus-related factors, the properties of the drugs used, and the 
treatment strategies applied. Patients who carry Resistant Associated Substitutions (RASs) may not obtain benefits from 
treatment, and are at a risk of disease progression.  Whether HCV RASs persist depends on their type: NS3-4A variants 
often disappear gradually after DAA therapy is stopped, whereas NS5A variants tend to persist for more than 2 years. The 
best way to prevent emergence of resistant variants is to eliminate the virus at the first treatment using highly potent 
DAAs with genetic barriers to resistance. For those who fail an NS5A inhibitor, deferral of treatment is recommended 
pending the availability of additional data if they do not have cirrhosis or reasons for urgent re-treatment. If re-treatment 
is needed, the most commonly used strategy is sofosbuvir as backbone therapy plus a drug from a class other than that 
previously used, for 24 weeks. Unless it is contraindicated, weight-based ribavirin should also be added. If available, 
nucleotide-based (eg, sofosbuvir) triple or quadruple DAA regimens may be considered. The optimal treatment for 
patients who fail an NS5A inhibitor and those with multidrug-resistant variants remains to be defined, and research 
efforts should continue to focus on treatment for these patients. (Clin Mol Hepatol 2016;22:432-438)
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such as DCV or LDV or VEL (the two latter in fixed-dose combina-
tions; 3) an NS3-4A protease inhibitor (PI), paritaprevir boosted 
with ritonavir (PTV/r) plus an NS5A inhibitor, OBV, in a fixed-dose 
combination with a non-nucleoside polymerase inhibitor, DSV (in 
GT4, DSV is not included in the regimen); 4) GZV/EBV in a fixed-
dose combination; and 5) DCV and ASV in some Asian countries. 
In patients infected by GT2 and GT3, the only approved regimens 
are SOF and RBV, and SOF with an NS5 inhibitor either DCV or 
VEL. In GT5 and GT6, the approved drugs are SOF combined with 
an NS5A inhibitor. Whichever of these regimens is used, sustained 
virologic response (SVR) rates in the registration studies involving 
GT1 and GT4 patients are higher than 90%, but SVR is lower in 
GT3 treatment-experienced patients. The safety profiles of these 
combinations, particularly RBV-free ones are excellent.
The results of treatment with these DAA regimens in various re-
al-world cohorts show high SVR rates (80%-90%). Variations in 
the SVR depend on the number of patients with decompensated 
liver disease and cirrhosis included in the studies.3-12 For patients 
with GT2 or GT3 infection, the first approved interferon-free regi-
men was SOF plus RBV for 12 to 24 weeks, which yielded SVR 
rates of 68% to 90%.13-15 In addition, three DAA combinations are 
available for GT3: SOF plus DCV, SOF/LDV and SOF/VEL.3 The ex-
tensive use of these regimens foresees that a fair number of pa-
tients will fail these newer antiviral treatments in the near future.
This review focusses on the management of patients who fail 
DAA regimens, paying special attention to NS5 failures. The types 
of failures, the characteristics of patients who fail, the role of HCV 
drug resistance testing, and the available rescue strategies are re-
viewed.
VARIABILITY OF HEPATITIS C VIRUS
Hepatitis C virus has a high turnover rate and an estimated half-
life of only 2 to 5 hours: 1010 to 1012 virions are produced and 
cleared per day in an infected patient.16-18 Because of the lack of 
proof-reading activity of the HCV-RNA-dependent RNA poly-
merase (NS5B) and the high replication activity of HCV, a large 
number of viral variants are continuously produced during infec-
tion (error rate, approximately 10-3 to 10-4 mutations per nucleo-
tide per genomic replication).18 Most of these variants are cleared 
by the host’s immune system or are unable to replicate because of 
a functional loss in the encoded proteins,19,20 but a large number 
survive and maintain a chronic infection. The frequency of HCV 
isolates depends on their replication efficacy and other known 
and unknown viral and host factors.21 The complex mixture of dif-
ferent but closely related genomes comprising the HCV population 
is known as a quasispecies. Typically, a dominant strain (wild-
type) is detectable within the viral quasispecies, along with strains 
present at lower frequencies. Therapy with DAAs that incom-
pletely suppress viral replication enables selection of preexisting 
strains with reduced susceptibility to the drugs administered, 
which play a role in treatment failure. The full clinical impact of 
HCV drug resistance, its implications in retreatment options, and 
the potential role of baseline resistance are issues lacking com-
plete answers. 
PATTERNS OF ANTIVIRAL FAILURE AND EMER-
GENGE OF RESISTANCE-ASSOCIATED VARIANTS
Failures to DAA combinations in pivotal trials are usually related 
to relapse, which is defined as serum HCV RNA below the level of 
quantitation at completion of therapy followed by a rebound to 
pretreatment levels once therapy is discontinued. Very few pa-
tients fail by virological breakthrough, defined by increases in pre-
viously undetectable HCV RNA, while they are still on antiviral 
treatment.
In both situations, virological relapse and breakthrough, a com-
mon finding is selection of RASs within the viral quasispecies.22 
Treatment-emergent RASs with specific amino acid substitutions 
result in decreases in the effectiveness of a particular drug and 
represent a developing therapeutic challenge for the clinicians 
managing these patients. Treatment-emergent RASs will persist 
depending on the DAAs used. RASs selected during treatment 
with a PI such as simeprevir are transient and disappear in a few 
months after discontinuing therapy. For example, in a phase-III 
trial including patients without cirrhosis, 17% and 3% of patients 
experienced a relapse in the groups receiving 8 weeks and 12 
weeks of SMV and SOF respectively.23 Among patients with com-
pensated cirrhosis treated for 12 weeks without RBV, 16% did not 
achieve SVR, including 3 with viral breakthrough and 13 relaps-
ers. Among 14 patients for whom sequencing data were avail-
able, 11 had RASs in the NS3 protease at the time of failure. No 
sofosbuvir RASs were detected.24 
RASs related to NS5A inhibitors persist over time and have an 
impact on the choice and efficacy of future treatment. The typical 
case is the fixed-dose combination of SOF/LDV. In an integrated 
analysis of various studies using this regimen, virological failure 
occurred in 2.4% of 2144 patients.25 NS5A RASs were present in 
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74% of 51 patients at the time of failure. Most patients included 
had HCV GT1a. RASs were detected at several positions: M28T, 
Q30R, L31M, H58D, and Y93H (Table 1). 
In some Asian countries such as Korea and Japan, the combina-
tion of ASV plus DCV is widely used for patients with HCV GT1b 
infection. This combination is not recommended for patients with 
GT1a or other genotypes, and it has not been approved in Europe 
or the United States (Table 2).  The main reason is the impact that 
baseline NS5A RASs have on the SVR. In a pooled analysis includ-
ing 979 patients with GT1b infection treated with ASV and DCV 
for 24 weeks, baseline RASs at positions L31F/I/M/V had a con-
siderable effect on SVR rates: 42% in 43 patients with RASs ver-
sus 88% in 936 patients without RASs at these positions.26 RASs 
in the NS3 protease did not affect SVR. These results indicate that 
patients with HCV GT1b with preexisting NS5A RASs at the L31 
position should not be treated with this regimen. The rate of viro-
logical failures to ASV and DCV was 14% in 437 patients without 
cirrhosis and 16% in 206 patients with cirrhosis. A relevant find-
ing of the studies analyzed was that two-thirds of patients experi-
enced on-treatment breakthrough or no virological response at 
the end of treatment, whereas one-third relapsed.26 In a multina-
tional, phase-III, multicohort study with ASV and DCV the most 
frequent RASs selected at treatment failure in GT1b patients were 
at position D168 of the NS3 protease and at position Y93 of the 













Non additon of RBV
Shorten duration of treatment
Failure to multiple 
DAAs
Table 2 :Factors related to the Host, the Virus and Treatment Regimen
Figure 1. Factors related to the Host, the Vi-
rus and Treatment Regimen. 
Table 1. Treatment emergent Resistants Associated Substitutions by 
Drug Classes
Drug classes Specific drug RASs
NS3-4A PIs Simeprevir: R155K, D168V, Q80K (at baseline)
Paritaprevir: R155K, D168V, Y56H
Grazoprevir: R155K, D168V
NS5A inhibitors Ledipasvir: M28T, Q30R, L31M, H58D, Y93H
Ombitasvir: M22T, Q30R, L31M, H58D, Y93H
Daclatasvir: M28T, Q30R, H58D, Y93H
Elbasvir: M28T, L31M, H58D, Y93H
Velpatasvir Q30R/L, L31M, Y93H
N S5B polymerase 
inhibitors
Sofosbuvir (nucleoside inhibitor): S282T
Dasabuvir (nonnucleoside inhibitor): C316Y
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CAUSES OF TREATMENT FAILURE
Treatment failure has been related to host factors, viral factors, 
and treatment-related factors. A combination of two or more fac-
tors is needed to result in treatment failure,28 as the presence of a 
single factor has a limited effect on the SVR. Among the host fac-
tors, interleukine 28B polymorpyism and cirrhosis are the most 
imporatntSeveral viral factors have been associated with a low 
SVR, such as GT1a, GT3, high viral load, and presence of some 
baseline RASs, but the impact of these factors depends on the 
DAA regimen used. The treatment-related factors include previous 
therapy, short therapy duration, and adherence (Fig. 1). 
METHODS FOR DETECTING RESISTANCE-AS-
SOCIATED VARIANTS
The genetic diversity of viral populations and resistance-associ-
ated variants has been traditionally assessed by population se-
quencing (ie, direct sequencing of a PCR product) or by clonal se-
quencing (ie, cloning of a PCR product into plasmid vectors, 
followed by direct sequencing). The lower limit of detection of di-
rect sequencing ranges from 15% to 25%.29 Clonal sequencing is 
more sensitive, but also more expensive and time-consuming. 
These limitations are overcome by a technique known as deep se-
quencing, which allows detection of minor variants present at fre-
quencies as low as 0.5%.20 
At present, none of these techniques are commercially available 
in Europe, but a number of laboratories are able to perform se-
quence analysis of the NS3-4A, NS5A, and NS5B regions. In the 
United States, these tests are commercially available, but they are 
costly and may not be covered by all insurances companies. Cur-
rently, baseline RAS testing to individually tailor therapy is not 
recommended for treatment-naïve patients. In treatment-experi-
enced patients with some genotypes (eg, GT1a) treated with cer-
tain combinations such as GZR and EBR, baseline RAS testing is 
recommended to decide on therapy duration and whether to in-
clude ribavirin in the regimen.3 In patients who have failed DAA 
treatment, testing for resistance-associated variants that confer 
decreased susceptibility to NS3 protease inhibitors and to NS5A 
inhibitors is recommended for HCV GT1 patients (regardless of the 
subtype) who have compensated cirrhosis or a reason for urgent 
retreatment.3 The results of these tests can help in selecting the 
retreatment drugs and therapy duration. 
 Retreatment of Failures to Interferon-free DAA 
regimens
The number of patients who have failed DAAs is still relatively 
low, and the available retreatment data do not suffice to estab-
lish strong recommendations. The HCV guidance recommenda-
tion of the AASLD and IDSA for non-cirrhotic patients who fail 
an NS5A inhibitor and have no reasons for urgent retreatment is 
deferral of treatment pending availability of data in HCV GT1 
patients.3 If retreatment is needed in patients receiving nucleo-
tide-based (eg, sofosbuvir) dual DAA therapy, treatment dura-
tion of 24 weeks is recommended, with addition of weight-
based ribavirin, unless contraindicated. If nucleotide-based (eg, 
sofosbuvir) triple or quadruple DAA regimens are available they 
may also be considered. In this setting, treatment duration 
ranges from 12 weeks to 24 weeks, and weight-based ribavirin 
is recommended. Nonetheless, the scientific evidence support-
ing these recommendations is scarce.  The following are the 
currently available retreatment data for several regimens:
Retreatment of SOF plus SMV failure
At present, there is relatively little information on salvage 
therapy for patients failing treatment with SOF plus SMV. How-
ever, as cross-resistance between NS3-4A and NS5A RAVs has 
been ruled out, potential retreatment options are combinations 
of an NS5A inhibitor plus SOF, such as SOF/LDV or SOF/DCV.30,31 
The appropriate treatment duration remains to be determined, 
but 24 weeks will likely be needed in patients with cirrhosis 
and when RBV is not included. RBV has the potential to short-
en the therapeutic regimen to 12 weeks. 
Retreatment of SOF plus RBV failure
Sofosbuvir plus RBV is no longer offered to GT1 patients be-
cause the response to this regimen is suboptimal, but it is still 
a viable option for GT2 and GT3 treatment-naïve patients in 
some countries. With regard to GT2 and GT3 infection, 107 
patients who failed SOF plus RBV in phase-II trials were re-
treated at the investigator’s discretion with SOF plus pegylated 
interferon (P) and RBV for 12 weeks or SOF plus RBV for 24 weeks. 
The preliminary results in GT3 patients showed a higher SVR rate 
in the SOF plus P/RBV 12-week arm (91% of 25 cases) than in the 
SOF plus RBV 24-week arm (63% of 38 cases ).32
In the registration studies for SOF/DCV with or without RBV, 
13 patients who failed SOF plus RBV have been retreated with 
SOF/DCV±RBV for either 12 or 16 weeks.33,34 In clinical prac-
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tice, 14 patients were retreated with SOF/DCV±RBV or LDV/
SOF and RBV for 24 weeks and all achieved a SVR 12.35 In ad-
dition, data on SOF/VEL and RBV for 24 weeks have been re-
ported in 17 GT3 patients. Thirteen of them (77%) achieved 
SVR. The presence of NS5A RASs at retreatment had an impact 
on the SVR. The numbers are small, but SVR was achieved in 
all patients (3/3) without baseline NS5A RASs compared to 
77% (10/13) of those with RASs.36
Retreatment of SOF/LDV or SOF/DCV failures
The SOF/LDV combination is now being widely used. Few 
patients are expected to fail this therapy, but failure may be an 
issue in specific populations, such as those with cirrhosis and 
comorbidities. Patients who have failed SOF/LDV or SOF/DCV 
harbor NS5A RAVs and may have variants conferring low sus-
ceptibility to SOF, although S282T mutations have not been 
detected in the phase-III studies to date (Table 3).
There is relatively little data on salvage therapy for SOF/LDV 
failures. Twenty-one patients who failed SOF-based regimens 
(including SOF/LDV) and harboring NS5B RAVs were retreated 
with SOF plus P/RBV for 12 weeks. Sixteen (76%) achieved 
SVR, a value similar to the retreatment rate in patients without 
RAVs.35  In the 5 patients who relapsed after retreatment, the 
L159F variant disappeared and V321A was not enriched.35
In another study, 41 GT1 patients who failed SOF/LDV, in-
cluding 19% with liver cirrhosis, received SOF/LDV for 24 
weeks.36 Thirty were prior failures to 8 weeks of SOF/LDV and 
the remaining 11 were failures to 12 weeks of this therapy. Pa-
tients previously treated for 8 weeks achieved a higher SVR 
rate (80%) than those previously treated for 12 weeks (46%). 
Baseline NS5A RAVs, detected in 19 patients, had an impact 
on SVR rates: SVR was 60% in the 30 patients with RAVs ver-
sus 100% in the 11 without. Patients having more than two 
RAVs had a lower SVR rate (50%) than those with only one 
(69%). The type of single NS5A RAV also influenced SVR, 
which was lower in patients carrying Y93H/N (only 2 of 6 
achieved SVR), suggesting that the complexity (number and 
type) of RAVs present matters.36 RBV was not included in the 
therapeutic regimen, so there was no opportunity to evaluate 
its potential role in this treatment combination. The above-men-
tioned study did not include the most difficult to rescue patients, 
those who fail 24 weeks of SOF/LDV. In these patients, HCV drug 
resistance testing would be useful for selecting the best salvage 
therapy, which should include RBV or new, more potent DAAs. 
The same would be true for failures to SOF/DCV, since the HCV 
drug resistance should be very similar. 
In another study, 22 GT1 patients who failed to respond to 
DAA therapy, including 16 who were exposed to an NS5A in-
hibitor, were retreated with SOF and OBV/PTV/r and DSV, with 
or without ribavirin, depending on the HCV subtype and pres-
ence of cirrhosis. The percentages of patients experiencing SVR 
were 92% (13/14) after 12 weeks with RBV in GT1a patients 
without cirrhosis, 100% (6/6) after 24 weeks with RBV in GT1a 
patients with cirrhosis, and 100% (2/2) after 12 weeks without 
RBV in GT1b patients.37
Twenty-three patients with GT1 infection who did not have 
an SVR after a first course of 4, 6, or 8 weeks of SOF and GZV/
EBV were re-treated for 12 weeks with the same combination. 
All of them achieved SVR.38
In another study, 69 patients (37 GT1, 14 GT2, and 18 GT3) 
who had failed prior VEL-containing regimens in phase-II stud-
ies were retreated with SOF/VEL+RBV for 24 weeks. SVR was 
observed in 97% of GT1, 91% of GT2 and 76% of GT3 pa-
tients. The presence of NS5A RASs at retreatment did not have 
an impact on SVR in GT1 and GT2.  No virologic failures oc-
curred in GT3 patients without RASs, but SVR decreased to 
77% in those with NS5A RASs.34
Some retreatment data have been reported from clinical 







Lawitz, et al. (2015)38 LDV/SOF 24 wks 1 41 71% 60% (18/30)
Hézode, et al. (2016)39 SOF+SMV 12 wks 1/4 14/2 87% 85% (11/13)
Poordad, et al. (2016) 37 3D+SOF±RBV 12-24 wks 1 22 95% 100% (17/17)
Gane, et al. (2016)36 SOF/VEL+RBV 24 weeks 1 34 97% 100% (6/6)
2 14 91% 100% (8/8)
3 17 76% 76.90% (10/13) 
RAS, resistant asocciated sustitutions.
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practice. Fifteen patients who failed to respond to DCV-based 
regimens were retreated with SOF and SMV±RBV for 12 
weeks; 87% (13/15) of them achieved SVR, including 8 of 10 
with GT1a, 3 of 3 with GT1b, and 2 of 2 with GT4 infection.39 
In a large European database, 192 DAA failures were identi-
fied. Retreatment was started in 23% (n=34) and 15% (n=4) 
of GT1 and GT3 patients, respectively. Of these, the majority 
of GT1 patients had failed SMV/SOF and they were restarted 
on either OMV, or PTV/r and DSV, or LDV/SOF. In GT3 patients, 
salvage therapy consisted of 24 weeks of SOF/DCV+RBV. In 
patients with available outcome data (n=14/38), 93% of HCV 
GT1 and 100% of GT3-infected patients achieved SVR with 
salvage therapy.35
Two phase-II studies have evaluated SOF/VEL and a new 
protease inhibitor, voxilaprevir (GS-9857) (100 mg) in a fixed-
dose combination for 12 weeks in treatment-experienced pa-
tients with or without cirrhosis infected with genotypes 1 to 6, 
including some who had been previously treated with DAAs.40 
In total, 128 patients (49% GT1, 16% GT2, 27% GT3, 5% 
GT4, and 2% GT6) were treated. Overall, 27% were NS5A-ex-
perienced, 52% were non-NS5A DAA-experienced, and 21% 
had no prior DAA experience. Baseline RAVs were detected in 
60% of patients (20% NS5A, 15% NS3, 2% NS5B (no S282 T), 
and 23% had resistance to multiple classes).  All patients ex-
cept one with GT3 infection achieved SVR. The GT3 patient 
who relapsed had cirrhosis and the NS5A RAV Y93H, detected 
at baseline. Relapse occurred at post-treatment week 8.
In summary, these results obtained from the available pub-
lished data indicate that current retreatment strategies can 
lead to SVR in a large percentage of patients who did not 
achieve SVR with previous DAA regimens, including those with 
RASs at the time of retreatment. The current evidence indicates 
that the best retreatment option is the combination of SOF 
with 1 to 3 other DAAs, as well as addition of ribavirin and/or 
prolongation of treatment duration to 24 weeks.
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